Regenxbio (RGNX) Receivables - Net (2014 - 2025)

Regenxbio's Receivables - Net history runs 12 years deep, the most recent figure standing at $28.7 million for Q4 2025.

• On a quarterly basis, Receivables - Net rose 36.97% year-over-year to $28.7 million in Q4 2025; TTM through Dec 2025 was $28.7 million, a 36.97% increase from a year earlier, with the FY2025 full-year figure at $28.7 million, up 36.97% from the prior year.
• Receivables - Net advanced to $28.7 million in Q4 2025 per RGNX's latest filing, from $28.1 million in the prior quarter.
• Across five years, Receivables - Net topped out at $48.7 million in Q3 2021 and bottomed at $16.4 million in Q1 2024.
• The 5-year median for Receivables - Net is $28.4 million (2025), against an average of $29.3 million.
• Across the five-year window, Receivables - Net sank 61.21% in 2021 and jumped 36.97% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $34.7 million in 2021, then decreased by 14.74% to $29.6 million in 2022, then decreased by 13.84% to $25.5 million in 2023, then fell by 17.83% to $20.9 million in 2024, then soared by 36.97% to $28.7 million in 2025.
• Per Business Quant, the three latest RGNX Receivables - Net figures stand at $28.7 million (Q4 2025), $28.1 million (Q3 2025), and $21.8 million (Q2 2025).